Mycosis fungoides/Sézary syndrome and systemic Janus kinase inhibitors: a real-world retrospective study on behalf of the EORTC CLTG
British Journal of Dermatology · 19.05.2026 · 194 (6) · 1178-1180
DOI: 10.1093/bjd/ljag089 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 09.03.2026. Verfasst von Iris Amitay-Laish und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
Janus kinase inhibitors (JAKis) are increasingly used in patients with mycosis fungoides (MF)/Sézary syndrome (SS), often outside of intentional lymphoma-directed treatment, yet their real-world impact remains uncertain and poorly characterized. Our multicentre experience suggests that disease acceleration may occur in specific clinical contexts, particularly in patients initially diagnosed with dermatitis who were later recognized as having MF/SS while receiving JAKis. It remains uncertain whether this acceleration represents a direct drug-related effect. Observations in post-transplant settings warrant further investigation, particularly given ruxolitinib’s role in this context. However, symptom-focused benefit may be observed in carefully selected patients. Collectively, these findings highlight that the use of JAKis in treating patients with MF/SS should be undertaken with caution.
Autor:innen und Institutionen
- Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel.
- Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
ORCID-Profile: Iris Amitay-Laish, Keila Mitsunaga, Pablo L Ortiz-Romero, Adèle de Masson, Erika Morsia, Jose A Sanches, Paula A Enz, Vasiliki Nikolaou, Constanze Jonak, Stefanie Porkert, Yael A Leshem, Emily Avitan-Hersh, Emmilia Hodak
Zitieren
APA
Amitay-Laish, I., Mitsunaga, K., Ortiz-Romero, P. L., de Masson, A., Morsia, E., Sanches, J. A., Enz, P. A., Nikolaou, V., Jonak, C., Porkert, S., Leshem, Y. A., Avitan-Hersh, E., & Hodak, E. (2026). Mycosis fungoides/Sézary syndrome and systemic Janus kinase inhibitors: a real-world retrospective study on behalf of the EORTC CLTG. British Journal of Dermatology, 194(6), 1178-1180. https://doi.org/10.1093/bjd/ljag089
Vancouver
Amitay-Laish I, Mitsunaga K, Ortiz-Romero PL, de Masson A, Morsia E, Sanches JA, et al. Mycosis fungoides/Sézary syndrome and systemic Janus kinase inhibitors: a real-world retrospective study on behalf of the EORTC CLTG. British Journal of Dermatology. 2026;194(6):1178-1180. doi:10.1093/bjd/ljag089
BibTeX
@article{AmitayLaish2026,
author = {Amitay-Laish, Iris and Mitsunaga, Keila and Ortiz-Romero, Pablo L and de Masson, Adèle and Morsia, Erika and Sanches, Jose A and Enz, Paula A and Nikolaou, Vasiliki and Jonak, Constanze and Porkert, Stefanie and Leshem, Yael A and Avitan-Hersh, Emily and Hodak, Emmilia},
title = {Mycosis fungoides/Sézary syndrome and systemic Janus kinase inhibitors: a real-world retrospective study on behalf of the EORTC CLTG},
journal = {British Journal of Dermatology},
year = {2026},
volume = {194},
number = {6},
pages = {1178--1180},
doi = {10.1093/bjd/ljag089}
}
EUVIMED